natgillin/translations-raw huggingface dataset:
the participant informed the Rapporteur Member State, at the time of submission of the dossier, that preparation of the additional information was under way;
deltakeren underrettet den rapporterende medlemsstaten, på tidspunktet for framlegging av dokumentasjonen, om at utarbeiding av tilleggsopplysningene var i gang,
the additional information is submitted no later than nine months after acceptance of the dossier in accordance with Article 13(3);
tilleggsopplysningene blir oversendt senest ni måneder etter at dokumentasjonen ble godkjent i samsvar med artikkel 13 nr. 3,
by comparison with the data originally submitted, the additional information is equally or more reliable owing to the application of the same or higher quality standards;
tilleggsopplysningene er minst like pålitelige som de opplysningene som opprinnelig ble framlagt fordi det er anvendt tilsvarende eller høyere kvalitetsstandarder,
by comparison with the data originally submitted, the additional information supports a different conclusion concerning the active substance for the purposes of the recommendation under paragraph 6.
tilleggsopplysningene, sammenlignet med de opplysningene som opprinnelig ble framlagt, fører til en annen konklusjon om det aktive stoffet med hensyn til anbefalingen omhandlet i nr. 6.
The Rapporteur Member State shall take into account additional information submitted by persons other than the participant only if that information satisfies the conditions set out in points (b), (c) and (d) of the first subparagraph.
Den rapporterende medlemsstaten skal ta hensyn til tilleggsopplysninger som er framlagt av andre enn deltakeren, bare dersom disse opplysningene oppfyller vilkårene fastsatt i bokstav b), c) og d) i første ledd.
Where relevant in the application of paragraph 1, in particular when additional information has been requested by a deadline established by the Rapporteur Member State, the latter may request that the participant submit updated summary dossiers to the Commission and the other Member States when the additional information is received.
Når det er relevant for anvendelsen av nr. 1, og særlig når det er blitt anmodet om tilleggsopplysninger innen en frist fastsatt av den rapporterende medlemsstaten, kan sistnevnte anmode deltakeren om å framlegge for Kommisjonen og de andre medlemsstatene et ajourført sammendrag av dokumentasjonen når tilleggsopplysningene er mottatt.
All participants shall be deemed to have withdrawn and Articles 11(2) and 12 shall apply
Alle deltakere skal anses for å ha trukket seg ut og artikkel 11 nr. 2 og artikkel 12 får tilsvarende anvendelse dersom
the participant fails to provide adequate justification for further postponing the deadline;
deltakeren ikke gir noen tilfredsstillende begrunnelse for at tidsfristen skal forlenges ytterligere,
A Rapporteur Member State may decide to withhold the competent authority report if the charges payable under Article 25 of Directive 98/8/EC have not been paid in full, in which case it shall inform the participant and the Commission accordingly.
En rapporterende medlemsstat kan beslutte å holde tilbake vedkommende myndighets rapport dersom gebyrene som skal betales i henhold til artikkel 25 i direktiv 98/8/EF, ikke er betalt i sin helhet, og skal i så fall underrette deltakeren og Kommisjonen om dette.
a recommendation to include the existing active substance in Annex I, IA or IB to Directive 98/8/EC, stating, where appropriate, conditions for inclusion;
en anbefaling om å oppføre det eksisterende aktive stoffet i vedlegg I, I A eller I B til direktiv 98/8/EF, eventuelt med angivelse av vilkårene for oppføring, eller
a recommendation not to include the existing active substance in Annex I, IA or IB to Directive 98/8/EC, stating the reasons.
en anbefaling om ikke å oppføre det eksisterende aktive stoffet i vedlegg I, I A eller I B til direktiv 98/8/EF, med angivelse av årsakene.
When the Commission receives a competent authority report pursuant to Article 14(4) of this Regulation it shall, without undue delay, prepare the draft decision referred to in Article 27 of Directive 98/8/EC.
Når Kommisjonen mottar vedkommende myndighets rapport i samsvar med artikkel 14 nr. 4 i denne forordning, skal den uten unødig opphold utarbeide et utkast til beslutning som nevnt i artikkel 27 i direktiv 98/8/EF.
Before preparing the draft decision referred to in paragraph 1, the Commission shall, when necessary in the light of the comments received on the competent authority report, consult with experts from the Member States to address any problems remaining unresolved.
Før utkastet til beslutning nevnt i nr. 1 utarbeides, skal Kommisjonen, dersom det i lys av kommentarene til vedkommende myndighets rapport er nødvendig, rådføre seg med sakkyndige fra medlemsstatene for å drøfte eventuelle uløste problemer.
Where an existing active substance, despite a recommendation for inclusion pursuant to Article 14(6) of this Regulation, still gives rise to concern, as referred to in Article 10(5) of Directive 98/8/EC, the Commission may, without prejudice to Article 12 of that Directive, take into account the finalisation of the evaluation of other existing active substances applied for the same use.
Dersom et eksisterende aktivt stoff til tross for en anbefaling om oppføring i henhold til artikkel 14 nr. 6 i denne forordning, fortsatt gir grunn til bekymring som nevnt i artikkel 10 nr. 5 i direktiv 98/8/EF, kan Kommisjonen, med forbehold for artikkel 12 i nevnte direktiv, ta hensyn til resultatet av vurderingen av andre eksisterende aktive stoffer som benyttes til samme formål.
On the basis of the documents and information referred to in Article 27(2) of Directive 98/8/EC, the Rapporteur Member State shall prepare an updated competent authority report, the first part of which shall form the assessment report.
På grunnlag av dokumentene og opplysningene nevnt i artikkel 27 nr. 2 i direktiv 98/8/EF skal den rapporterende medlemsstaten utarbeide en ajourført rapport fra vedkommende myndighet, der vurderingsrapporten skal utgjøre første del.
The assessment report shall be reviewed within the Standing Committee on Biocidal Products.
Vurderingsrapporten skal gjennomgås i Den faste komité for biocidprodukter.
Where several dossiers have been submitted for the same active substance/product type combination, the Rapporteur Member State shall prepare one assessment report based on the information contained in those dossiers.
Dersom flere har lagt fram dokumentasjon for den samme kombinasjonen av eksisterende aktivt stoff og produkttype, skal den rapporterende medlemsstaten utarbeide én vurderingsrapport basert på opplysningene i de ulike utgavene av denne dokumentasjonen.
Where a Rapporteur Member State has submitted the competent authority report in accordance with Article 14(4) of this Regulation, or where an assessment report has been finalised or updated in the Standing Committee on Biocidal Products, the Commission shall make the report or any updates thereof publicly available by electronic means, except for information that is to be treated as confidential in accordance with Article 19 of Directive 98/8/EC.
Når den rapporterende medlemsstaten har framlagt rapporten fra vedkommende myndighet i samsvar med artikkel 10 nr. 5 i denne forordning, eller dersom en vurderingsrapport er blitt sluttbehandlet eller ajourført av Den faste komité for biocidprodukter, skal Kommisjonen offentliggjøre rapporten eller eventuelle ajourføringer elektronisk, med unntak av opplysninger som skal behandles som fortrolige i samsvar med artikkel 19 i direktiv 98/8/EF.
Where, in respect of an active substance listed in Annex II to this Regulation, the Commission presents a proposal for amending Directive 76/769/EEC or, with effect from 1 June 2009, Annex XVII of Regulation (EC) No 1907/2006 in order to prohibit its placing on the market or its use, including use for biocidal purposes, in certain or all product types, the procedures provided for in this Regulation concerning that substance for use in the product types concerned may be suspended pending a decision on that proposal.
Dersom Kommisjonen, for et aktivt stoff oppført i vedlegg II til denne forordning, legger fram et forslag om å endre direktiv 76/769/EØF eller, med virkning fra 1. juni 2009, vedlegg XVII til forordning (EF) nr. 1907/2006 med det formål å forby omsetning eller bruk av stoffet, herunder for bruk som biocid, i visse eller alle produkttyper, kan framgangsmåtene fastsatt i denne forordning med hensyn til dette stoffet og bruken av det i de aktuelle produkttypene utsettes i påvente av en beslutning om det nevnte forslaget.
Regulation (EC) No 2032/2003 is repealed.
Forordning (EF) nr. 2032/2003 oppheves.
ACTIVE SUBSTANCES IDENTIFIED AS EXISTING
AKTIVE STOFFER IDENTIFISERT SOM EKSISTERENDE AKTIVE STOFFER
Glycerol trinitrate
Glyseroltrinitrat
Ethinylestradiol
Etinyløstradiol
Coumachlor
Kumaklor
Chloroxylenol
Klorxylenol
Biphenyl-2-ol
2-fenylfenol / bifenyl-2-ol
Dichlorophen
Diklorofen
Chlorphenesin
Klorfenesin
Citronellol
Sitronellol
Ethane-1,2-diol
Etylenglykol / 1,2-etandiol
m-Cresol
m-kresol
(Z)-docos-13-enoic acid
(Z)-dokos-13-ensyre
1,7,7-trimethylbicyclo[2.2.1]hept-2-yl thiocyanatoacetate
1,7,7-trimetylbisyklo(2.2.1)hept-2-yltiocyanatoacetat
1,3-dichloro-5,5-dimethylhydantoin
1,3-diklor-5,5-dimetylhydantoin
Sodium 2-biphenylate
Natrium-2-bifenylat / natriumbifenyl-2-yloksid
Disodium cyanodithiocarbamate
Dinatriumcyanoditiokarbamat
2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one
2-hydroksy-4-isopropyl-2,4,6-sykloheptatrien-1-on
1-isopropyl-4-methylbicyclo[3.1.0]hexan-3-one
1-isopropyl-4-metylbisyklo[3.1.0]heksan-3-on
[4-[4,4′-bis(dimethylamino)benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium chloride
[4-[4,4′-bis(dimetylamino)benzhydryliden]sykloheksa-2,5-dien-1-yliden]dimetylammoniumklorid
Dodecyltrimethylammonium bromide
Dodecyltrimetylammoniumbromid
4,5-dichloro-3H-1,2-dithiol-3-one
4,5-diklor-3H-1,2-ditiol-3-on
Didecyldimethylammonium bromide
Didecyldimetylammoniumbromid
2-bromo-1-(4-hydroxyphenyl)ethan-1-one
2-brom-1-(4-hydroksyfenyl)etan-1-on
(R)-p-mentha-1,8-diene
(R)-p-menta-1,8-dien / d-limonen
Dithallium sulphate
Ditalliumsulfat
Sodium fluoride
Natriumfluorid
7a-ethyldihydro-1H,3H,5H-oxazolo[3,4-c]oxazole
7a-etyldihydro-1H,3H,5H-oksazolo[3,4-c]oksazol
Sodium chlorate
Natriumklorat
Castor oil
Ricinusolje
Bone oil/Animal oil
Beinolje / dyreolje (dippelsolje)
Tar, pine/Pine wood tar
Furutjære / tjære av furutre
Tall-oil rosin
Talloljekolofonium
Asphalt/Bitumen
Asfalt / bitumen
p-[(diiodomethyl)sulphonyl]toluene
p-[(dijodmetyl)sulfonyl]toluen
Disilver oxide
Disølvoksid
Calcium magnesium oxide/dolomitic lime
Kalsiummagnesiumoksid / dolomittkalk
ethyl N-acetyl-N-butyl-.beta.-alaninate
etyl-N-acetyl-N-butyl-.beta.-alaninat
3-iodo-2-propynyl butylcarbamate
3-jod-2-propynylbutylkarbamat
2-chloro-N-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]benzamide
2-klor-N-[[[4-(trifluormetoksy)fenyl]amino]karbonyl]benzamid
.alpha.-cyano-3-phenoxybenzyl [1R-[1.alpha.(S*),3.alpha.]]-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
.alfa.-cyano-3-fenoksybenzyl [1R-[1.alfa.(S*),3.alfa.]]-3-(2,2-diklorvinyl)-2,2-dimetylsyklopropankarboksylat
N-cyclopropyl-1,3,5-triazine-2,4,6-triamine
N-syklopropyl-1,3,5-triazin-2,4,6-triamin
1,3-dichloro-5-ethyl-5-methylimidazolidine-2,4-dione
1,3-diklor-5-etyl-5-metylimidazolidin-2,4-dion
Lithium 3-oxo-1,2(2H)-benzisothiazol-2-ide
Litium-3-okso-1,2(2H)-benzisotiazol-2-id
N-cyclohexyl-S,S-dioxobenzo[b]tiophene-2-carboxamide
N-sykloheksyl-S,S-dioksobenzo[b]tiofen-2-karboksamid
cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride
cis-1-(3-klorallyl)-3,5,7-triaza-1-azoniaadamantanklorid
3-benzo(b)thien-2-yl-5,6-dihydro-1,4,2-oxathiazine,4-oxide
3-benzo(b)tien-2-yl-5,6-dihydro-1,4,2-oksatiazin,4-oksid
(E)-2-Octadecenal
(E)-2-oktadecenal
(1S,2R,5S)-2-Isopropenyl-5-methylcyclohexanol
(1S,2R,5S)-2-isopropenyl-5-metylsykloheksanol
Tris(N-cyclohexyldiazeniumdioxy)aluminium
Tris(N-sykloheksyldiazeniumdioksy)aluminium
2-bromo-1-(2,4-dichlorophenyl)vinyl diethyl phosphate/bromfenvinfos
2-bromo-1-(2,4-diklorfenyl)vinyldietylfosfat / bromfenvinfos
Plant protection Product
Plantevernmiddel
[1.alpha.(S*),3.alpha.]-(.alpha.)-Cyano-(3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dichlorovinyl)-2,2-dimenthylcyclopropanecarboxylate
[1.alfa.(S*),3.alfa.]-(.alfa.)-cyano-(3-fenoksyfenyl)metyl-3-(2,2-dikloretenyl)-2.2-diklorvinyl)-2,2-dimetylsyklopropankarboksylat
Natural Polymer
Naturlig polymer
Eucalyptus Oil
Eukalyptusolje
Cypress Oil
Sypressolje
Rue oil
Vinruteolje
Bois de rose oil/Rosewood oil
Rosentreolje
Natural extract
Naturlig ekstrakt
ACTIVE SUBSTANCES TO BE EXAMINED UNDER THE REVIEW PROGRAMME
AKTIVE STOFFER SOM SKAL UNDERSØKES SOM LEDD I VURDERINGSPROGRAMMET
2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether/Piperonyl butoxide
2-(2-butoksyetoksy)etyl-6-propylpiperonyleter / piperonylbutoksid
(2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo[2,3-h]chromen-6-one/Rotenone
(2R,6aS,12aS)-1,2,6,6a,12,12a-heksahydro-2-isopropenyl-8,9-dimetoksykromeno[3,4-b]furo[2,3-h]kromen-6-on / rotenon
Undecan-2-one/Methyl-nonyl-ketone
Undekan-2-on / metylnonylketon
N-(trichloromethylthio)phthalimide/Folpet
N-(triklormetyltio)ftalimid / folpet
Dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide/Tolylfluanid
Diklor-N-[(dimetylamino)sulfonyl]fluor-N-(p-tolyl)metansulfenamid / tolylfluanid
(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate/d-trans-Tetramethrin
(1,3,4,5,6,7-heksahydro-1,3-diokso-2H-isoindol-2-yl)metyl (1R-trans)-2,2-dimetyl-3-(2-metylprop-1-enyl)syklopropankarboksylat/d-transtetrametrin
Calcium oxide/lime/burnt lime/quicklime
Kalsiumoksid / kalk / brent kalk / ulesket kalk
4-(2-nitrobutyl)morpholine
4-(2-nitrobutyl)morfolin
Sodium dichloroisocyanurate dihydrate
Natriumdiklorisocyanuratdihydrat
Hydrogen chloride/Hydrochloric acid
Hydrogenklorid / saltsyre
Disodium peroxodisulphate/Sodium persulphate
Dinatriumperoksodisulfat / natriumpersulfat
Sodium hydrogen 2,2′methylenebis[4-chlorophenolate]
Natriumhydrogen 2,2′metylenbis[4-klorfenolat]
Hexaboron dizinc undecaoxide/Zinc borate
Heksabordisinkundekaoksid / sinkborat
(benzyloxy)methanol
(Benzyloksy)metanol
(benzothiazol-2-ylthio)methyl thiocyanate
(Benzotiazol-2-yltio)metyltiocyanat
2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate/Prallethrin
2-metyl-4-okso-3-(prop-2-ynyl)syklopent-2-en-1-yl-2,2-dimetyl-3-(2-metylprop-1-enyl)syklopropankarboksylat / pralletrin
3-[3-(4′-bromo[1,1′-biphenyl]-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2-benzopyrone/Bromadiolone
3-[3-(4′-brom[1,1′-bifenyl]-4-yl)-3-hydroksy-1-fenylpropyl]-4-hydroksy-2-benzopyron / bromadiolon
3-(4-isopropylphenyl)-1,1-dimethylurea/Isoproturon
3-(4-isopropylfenyl)1,1-dimetylurea / isoproturon
1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole/Imazalil
1-[2-(allyloksy)-2-(2,4-diklorfenyl)etyl]-1H-imidazol / imazalil
S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate/Azamethiphos
S-[(6-klor-2-oksooksazolo[4,5-b]pyridin-3(2H)-yl)metyl] O,O-dimetyltiofosfat / azametifos
Calcium magnesium tetrahydroxide/calcium magnesium hydroxide/hydrated dolomitic lime
Kalsiummagnesiumtetrahydroksid / kalsiummagnesiumhydroksid / hydratisert dolomittkalk
.alpha.-cyano-3-phenoxybenzyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate
.alfa.-cyano-3-fenoksybenzyl 2,2-dimetyl-3-(2-metylprop-1-enyl)syklopropankarboksylat
Mixture of cis- and trans-p-menthane-3,8 diol/Citriodiol
Blanding av cis- og trans-p-mentan-3,8-diol / citriodiol
.alpha.-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate/Cypermethrin
.alfa.-cyano-3-fenoksybenzyl 3-(2,2-diklorvinyl)-2,2-dimetylsyklopropankarboksylat / cypermetrin
.alpha.-cyano-3-phenoxybenzyl [1R-[1.alpha.(S*),3.alpha.]]-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate/Deltamethrin
.alfa.-cyano-3-fenoksybenzyl-(1R-[1.alfa.(S*),3.alfa]]-3-(2,2-dibromvinyl)-2,2-dimetylsyklopropankarboksylat / deltametrin
1-ethynyl-2-methylpent-2-enyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate/Empenthrin
1-etynyl-2-metylpent-2-enyl 2,2-dimetyl-3-(2-metylprop-1-enyl)syklopropankarboksylat / empentrin
3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin/Difenacoum
3-(3-bifenyl-4-yl-1,2,3,4-tetrahydro-1-naftyl)-4-hydroksykumarin / difenakum
4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin/Brodifacoum
4-hydroksy-3-(3-(4’-brom-4-bifenylyl)-1,2,3,4-tetrahydro-1-naftyl)kumarin / brodifakum
1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole/Propiconazole
1-[[2-(2,4-diklorfenyl)-4-propyl-1,3-dioksolan-2-yl]metyl]-1H-1,2,4-triazol / propikonazol
3,3′-methylenebis[5-methyloxazolidine]/Oxazolidin
3,3′-metylenbis[5-metyloksazolidin] / oksazolidin
.alpha.-cyano-4-fluoro-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate/Cyfluthrin
.alfa.-cyano-4-fluor-3-fenoksybenzyl-3-(2,2-diklorvinyl)-2,2-dimetylsyklopropankarboksylat / cyflutrin
ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate/Fenoxycarb
Etyl[2-(4-fenoksyfenoksy)etyl]karbamat / fenoksykarb
1-[1,3-bis(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]-1,3-bis(hydroxymethyl)urea/Diazolidinylurea
1-[1,3-bis(hydroksymetyl)-2,5-dioksoimidazolidin-4-yl]-1,3-bis(hydroksymetyl)urea / diazolidinylurea
Dihydrogen bis[monoperoxyphthalato(2-)-O1,OO1]magnesate(2-) hexahydrate
Dihydrogenbis[monoperoksyftalato(2-)-O1,OO1]magnesat(2-) heksahydrat
1-(3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl)-3-(2,6-difluorobenzoyl)urea/Hexaflumuron
1-(3,5-diklor-4-(1,1,2,2-tetrafluoretoksy)fenyl)-3-(2,6-difluorbenzoyl)urea / heksaflumuron
1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol/Tebuconazole
1-(4-klorfenyl)-4,4-dimetyl-3-(1,2,4-triazol-1-ylmetyl)pentan-3-ol / tebukonazol
2,3,5,6-tetrafluorobenzyl trans-2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate/Transfluthrin
2,3,5,6-tetrafluorbenzyl-trans-2-(2,2-diklorvinyl)-3,3-dimetylsyklopropankarboksylat / transflutrin
5,5-dimethyl-perhydro-pyrimidin-2-one .alpha.-(4-trifluoromethylstyryl)-.alpha.-(4-trifluoromethyl)cinnamylidenehydrazone/Hydramethylnon
5,5-dimetyl-perhydro-pyrimidin-2-on .alfa.-(4-trifluormetylstyryl)-.alfa.-(4-trifluormetyl)cinnamylidenhydrazon / hydrametylnon
3-phenoxybenzyl-2-(4-ethoxyphenyl)-2-methylpropylether/Etofenprox
3-fenoksybenzyl-2-(4-etoksyfenyl)-2-metylpropyleter / etofenproks
alpha-cyano-3-phenoxybenzyl (Z)-(1R,3R)-[(S)-3-(2-chloro-3,3,3-trifluoro-prop-1-enyl)]-2,2-dimethylcyclopropanecarboxylate;alpha-cyano-3-phenoxybenzyl (Z)-(1S,3S)-[(R)-3-(2-chloro-3,3,3-trifluoro-prop-1-enyl)]-2,2-dimethylcyclopropanecarboxylate/Lambda cyhalothrin
alfa-cyano-3-fenoksybenzyl(Z)-(1R,3R)-[(S)-3-(2-klor-3,3,3-trifluorpropenyl)]-2,2-dimetylsyklopropankarboksylat; alfa-cyano-3-fenoksybenzyl(Z)-(1S,3S)-[(R)-3-(2-klor-3,3,3-trifluor-propenyl)]-2,2-dimetylsyklopropankarboksylat / lambda-cyhalotrin
1-(4-(2-cloro-a,a,a-p-trifluorotolyloxy)-2-fluorophenyl)-3-(2,6-difluorobenzolyl)urea/Flufenoxuron
1-(4-(2-klor-a,a,a-p-trifluortolyloksy)-2-fluorfenyl)-3-(2,6-difluorbenzolyl)urea / flufenoksuron
cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin; trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin/Flocoumafen
cis-4-hydroksy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluormetylbenzyloksy)fenyl)-1-naftyl)kumarin; trans-4-hydroksy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluormetylbenzyloksy)fenyl)-1-naftyl)kumarin / flokumafen
sec-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate/Icaridine
sec-butyl 2-(2-hydroksetyl)piperidin-1-karboksylat / icaridin
1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine/Imidacloprid
1-(6-klorpyridin-3-ylmetyl)-N-nitroimidazolidin-2-ylidenamin / imidakloprid
[2,4-Dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate;[2,4-Dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate/Imiprothrin
[2,4-dioks-(2-propyn-1-yl)imidazolidin-3-yl]metyl(1R)-cis-chrysanthemat;[2,4-diokso-(2-propyn-1-yl)imidazolidin-3-yl]metyl(1R)-trans-chrysanthemat / imiprotrin
2-(1-methyl-2-(4-phenoxy-phenoxy)-ethoxy)-pyridine/Pyriproxyfen
2-(1-metyl-2-(4-fenoksy-fenoksy)-etoksy)-pyridin / pyriproksyfen
Reaction product of dimethyl adipate, dimethyl glutarate, dimethyl succinate with hydrogen peroxide/Perestane
Reaksjonsprodukt av dimetyladipat, dimetylglutarat, dimetylsuksinat med hydrogenperoksid / perestan
(E)-1-(2-Chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine/Chlothianidin
(E)-1-(2-klor-1,3-tiazol-5-ylmetyl)-3-metyl-2-nitroguanidin / klotianidin
Cyclohexylhydroxydiazene 1-oxide, potassium salt
Sykloheksylhydroksydiazen-1-oksid, kaliumsalt
Quaternary ammonium iodides
Kvaternære ammoniumjodider
Mixture of EINECS listed substances
Blanding av EINECS-oppførte stoffer
Silver-zinc-aluminium-boronphosphate glass/Glass oxide, silver- and zinc-containing
Sølv-sink-aluminium-borfosfatglass / glassoksid, sølv- og sinkholdig
(±)-1-(.beta.-allyloxy-2,4-dichlorophenylethyl)imidazole/Technical grade imazalil
(±)-1-(.beta.-allyloksy-2,4-diklorfenyletyl)imidazol / teknisk imazalil
S-Methoprene/Isopropyl (s-(E,E))-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate
S-Metopren / isopropyl-(s-(E,E))-11-metoksy-3,7,11-trimetyldodeka-2,4-dienoat
Esfenvalerate/(S)-.alpha.-Cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate
Esfenvalerat / (S)-alfa-cyano-3-fenoksybenzyl-(S)-2-(4-klorfenyl)-3-metylbutyrat
[1.alpha.(S*),3.alpha.]-(.alpha.)-cyano-(3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2.2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate/alpha-Cypermethrin
[1.alfa.(S*),3.alfa.]-(.alfa.)-cyano-(3-fenoksyfenyl)metyl-3-(2,2-dikloretenyl)-2.2-diklorvinyl)-2,2-dimetylsyklopropankarboksylat / alfa-cypermetrin
Cyclopropanecarboxylic acid, 3-[(1Z)-2-chloro-3,3,3-trifluoro-1-propenyl]-2,2-dimethyl-, (2-methyl[1,1′-biphenyl]-3-ylmethyl ester, (1R,3R)-rel-/Bifenthrin/Biphenate
Syklopropankarboksylsyre, 3-[(1Z)-2-klor-3,3,3-trifluor-1-propenyl]-2,2-dimetyl-, (2-metyl[1,1′-bifenyl]-3-ylmetyl-ester, (1R,3R)-rel- / bifentrin / bifenat
.alpha.-(4-Chlorophenyl)-.alpha.-(1-cyclopropylethyl)-1H-1,2,4-triazole-1-ethanol/Cyproconazole
.alfa.-(4-klorfenyl)-.alfa.-(1-syklopropyletyl)-1H-1,2,4-triazol-1-etanol / cyprokonazol
3-(3-(4′-Bromo-(1,1′-biphenyl)-4-yl)-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxybenzothiopyran-2-one/3-((RS,3RS;1RS,3SR)-3-(4′-bromobiphenyl-4-yl-1,2,3,4-tetrahydro-1-napthyl)-4-hydroxy-1-benzothin-2-one/Difethialone
3-(3-(4′-brom-(1,1′-bifenyl)-4-yl)-1,2,3,4-tetrahydro-1-naftyl)-4-hydroksybenzotiopyran-2-on / 3-((RS,3RS;1RS,3SR)-3-(4′-brombifenyl-4-yl-1,2,3,4-tetrahydro-1-naftyl)-4-hydroksy-1-benzotin-2-on / difetialon
4-Bromo-2-(4-chlorophenyl)-1-(ethoxymethyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile/Chlorfenapyr
4-brom-2-(4-klorofenyl)-1-(etoksymetyl)-5-(trifluormetyl)-1H-pyrrol-3-karbonitril / klorfenapyr
Aluminium sodium silicate-silver complex/Silver zeolite
Aluminiumnatriumsilikat-sølv-kompleks / sølvzeolitt
Aluminium sodium silicate-silver zinc complex/Silver-Zinc-Zeolite
Aluminiumnatriumsilikat-sølv-sink-kompleks / sølvsinkzeolitt
N-((6-Chloro-3-pyridinyl)methyl)-N′-cyano-N-methylethanimidamide/Acetamiprid
N-((6-klor-3-pyridinyl)metyl)-N′-cyano-N-metyletanimidamid / acetamiprid
3-phenoxybenzyl (1R)-cis,trans-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate/d-Phenothrin
3-fenoksybenzyl (1R)-cis,trans-2,2-dimetyl-3-(2-metylprop-1-enyl)syklopropankarboksylat / d-fenotrin
Mixture of 5-Hydroxymethoxymethyl-1-aza-3,7-dioxabicyclo(3.3.0)octane (CAS 59720-42-2, 16,0 %) and 5-Hydroxy-1-aza-3,7-dioxabicyclo(3.3.0)octane (EINECS 229-457-6, 28,8 %), and 5-Hydroxypoly[methyleneoxy]methyl-1-aza-3,7-dioxabicyclo(3.3.0)octane (CAS 56709-13-8; 5,2 %) in water (50 %)
Blanding av 5-hydroksymetoksymetyl-1-aza-3,7-dioksabisyklo(3.3.0)oktan (CAS 59720-42-2, 16,0 %) og 5-hydroksy-1-aza-3,7-diokaabisyklo(3.3.0)oktan (EINECS 229-457-6, 28,8 %), og 5-hydroksypoly[metylenoksy]metyl-1-aza-3,7-dioksabisyklo(3.3.0)oktan (CAS 56709-13-8; 5,2 %) i vann (50 %)